AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Vikas Sinha
President and Chief Financial Officer
Jeroen Van Beek
Chief Commercial Officer
Agustin Melian
Chief Medical Officer, Head of Global Medical Sciences
Ann Leen
Chief Scientific Officer
Edward Miller
General Counsel
Dana Alexander
SVP of Technical Operations
Mike Paglia
SVP of CMC Operations
Medha Chadha
SVP of Strategic Planning & Investor Relations

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.